Platelets are thought to aid in hemostasis, thrombosis, inflammation, wound healing, and immunity. R4 is a novel thiazole derivative that may decrease angina and ischemia. An aggregometer evaluated R4 impact on PRP. Spectrophotometric method measured anti-lipoxygenase activity of R4. In its absence, the platelet aggregation in PRP showed 88 % and 75 % with collagen and ADP, respectively, while R4 inhibited 100 % collagen-induced platelet aggregation at 1.1875 μM and ADP-induced platelet aggregation up to 100 % at 0.9375 μM. Collagen and ADP induced R4 antiplatelet IC50 values were 0.55 ± 0.12 μM, and 0.26 ± 0.20 μM, respectively. R4 inhibited lipoxygenase significantly with an IC50 of 26.65 ± 0.16 μM. The novel compound, R4, may also assist platelet-associated thromboembolic disorders.